We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > chronic hepatitis C

News List

CFDA approves Gilead’s Sovaldi for chronic hepatitis C treatment pharmaceufical-technology
September 27, 2017
The China Food and Drug Administration (CFDA) has approved Gilead Sciences’ Sovaldi (sofosbuvir at 400mg) for the treatment of patients with chronic hepatitis C virus (HCV) infection.
China FDA approves country’s first all-oral regimen for chronic hepatitis C, Daklinza in combination cphi-online
May 02, 2017
Daklinza and Sunvepra combination approved for genotype 1b, the most common chronic hepatitis C (HCV) genotype in China; combination has a 91-99% cure rate.
Health Canada Grants Priority Review to AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir americanpharmaceuticalreview
February 06, 2017
AbbVie has submitted a New Drug Submission (NDS), and received priority review from Health Canada, for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of all major chronic hepatitis C viru